ASIAMEDIC LIMITED
(Incorporated in the Republic of Singapore)
Company Registration No.: 197401556E

RECONSTITUTION OF BOARD COMMITTEES
RE-DESIGNATION OF LEAD INDEPENDENT DIRECTOR TO INDEPENDENT DIRECTOR

The Board of Directors of AsiaMedic Limited (the "**Company**") wishes to announce the reconstitution of the Board Committees as follows with effect from 1 January 2020:

Nominating Committee

Mr Chua Keng Woon (Chairman)	(Independent Director)
Mr Lawrence Peter Lim Hong Haw	(Independent Director)
Mr Tan Soo Kiat	(Non-Executive Director)

Mr Lawrence Lim is appointed a member of the Nominating Committee in place of Mr Goh Kian Chee.

Remuneration Committee

Mr Goh Kian Chee (Chairman)	(Independent Director)
Mr Lawrence Peter Lim Hong Haw	(Independent Director)
Mr Charles Wang Chong Guang	(Non-Executive Chairman)

Mr Charles Wang and Mr Lawrence Lim are appointed members of the Remuneration Committee in place of Mr Tan Soo Kiat and Mr Chua Keng Woon.

Audit and Risk Management Committee

There is no change to the Audit and Risk Management Committee comprising:

Mr Goh Kian Chee (Chairman)	(Independent Director)
Mr Chua Keng Woon	(Independent Director)
Mr Tan Soo Kiat	(Non-Executive Director)

Lead Independent Director

Mr Goh Kian Chee will relinquish his appointment as Lead Independent Director. However, Mr Goh will remain as an Independent Director of the Company.

The Code of Corporate Governance requires the board to have a lead independent director to provide leadership in situations where the chairman is conflicted, and especially when the chairman is not independent. The Company's Chairman is not independent. However, the Board has considered the Group's current business scale and operations and noted that three out of its five board members are Independent Directors. Accordingly, there is no need for a Lead Independent Director. The Board will review the need for the appointment of a Lead Independent Director periodically.

By Order of the Board

Foo Soon Soo (Ms)
Secretary

31 December 2019

This announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd, in compliance with Rule 226 of the Rules of Catalist. It has not been examined or approved by the Singapore Exchange Securities Trading Limited ("SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 63194954.